Pulmonary Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 125 molecules are developed by Companies and remaining by the Universities/Institutes. latest report Pulmonary Fibrosis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request sample at https://marketreportscenter.com/request-sample/438512
Pulmonary Fibrosis Pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. Pulmonary fibrosis can be caused by many conditions, including chronic inflammatory processes (like sarcoidosis or Wegener’s granulomatosis), infections, environmental agents (asbestos, silica, exposure to certain gases), and exposure to ionizing radiation. Symptoms include shortness of breath, dry cough, fatigue and aching muscles and joints. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 84 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 3 molecules, respectively.
Check Discount at https://marketreportscenter.com/request-discount/438512
Furthermore, this report also reviews of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects. Driven by data built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Know more details of report, Table of content, list of figures or purchase report at https://marketreportscenter.com/reports/438512/pulmonary-fibrosis-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center